Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David J Graham

Showing results (151-160 of 166) with videos related to

Pageof 17
Sort By:
The American Journal of Medicine|July 27, 2013
Cardiovascular risk in rheumatoid arthritis: comparing TNF-α blockade with nonbiologic DMARDsDaniel H Solomon, Jeffrey R Curtis, Kenneth G Saag, et al.
JAMA|November 18, 2015
Comparative Risk of Anaphylactic Reactions Associated With Intravenous Iron ProductsCunlin Wang, David J Graham, Robert C Kane, et al.
Annals of Internal Medicine|November 18, 2024
The Effect of Denosumab on Risk for Emergently Treated Hypocalcemia by Stage of Chronic Kidney Disease : A Target Trial EmulationSteven T Bird, Kate Gelperin, Elizabeth R Smith, et al.
JAMA|January 19, 2024
Severe Hypocalcemia With Denosumab Among Older Female Dialysis-Dependent PatientsSteven T Bird, Elizabeth R Smith, Kate Gelperin, et al.
Journal of the National Cancer Institute|October 6, 2023
Trends in new and persistent opioid use in older adults with and without cancerLaura Van Metre Baum, Madhav Kc, Pamela R Soulos, et al.
JAMA Oncology|December 20, 2019
Idelalisib for Treatment of Relapsed Follicular Lymphoma and Chronic Lymphocytic Leukemia: A Comparison of Treatment Outcomes in Clinical Trial Participants vs Medicare BeneficiariesSteven T Bird, Fang Tian, Natasha Flowers, et al.
JAMA Internal Medicine|October 25, 2016
Association Between Changes in CMS Reimbursement Policy and Drug Labels for Erythrocyte-Stimulating Agents With Outcomes for Older Patients Undergoing Hemodialysis Covered by Fee-for-Service MedicareCunlin Wang, Robert Kane, Mark Levenson, et al.
Leukemia|June 11, 2020
Second cancers in adults with acute promyelocytic leukemia treated with or without arsenic trioxide: a SEER-medicare analysisKelly J Norsworthy, Armen Avagyan, Steven T Bird, et al.
Pharmacoepidemiology and Drug Safety|November 10, 2025
Validation of the US Food and Drug Administration's COVID-19 Disease Severity Categorization for Use in Real-World DataSilvia Perez-Vilar, Wei Hua, Andrew Kwist, et al.
Cancer|September 22, 2025
Opioid prescribing trends and pain scores among adult patients with cancer in a large health systemLaura Van Metre Baum, Pamela R Soulos, Madhav Kc, et al.
Pageof 17

Showing results (151-160 of 166) with videos related to

Sort By:
Pageof 17
The American Journal of Medicine|July 27, 2013
Cardiovascular risk in rheumatoid arthritis: comparing TNF-α blockade with nonbiologic DMARDsDaniel H Solomon, Jeffrey R Curtis, Kenneth G Saag, et al.
JAMA|November 18, 2015
Comparative Risk of Anaphylactic Reactions Associated With Intravenous Iron ProductsCunlin Wang, David J Graham, Robert C Kane, et al.
Annals of Internal Medicine|November 18, 2024
The Effect of Denosumab on Risk for Emergently Treated Hypocalcemia by Stage of Chronic Kidney Disease : A Target Trial EmulationSteven T Bird, Kate Gelperin, Elizabeth R Smith, et al.
JAMA|January 19, 2024
Severe Hypocalcemia With Denosumab Among Older Female Dialysis-Dependent PatientsSteven T Bird, Elizabeth R Smith, Kate Gelperin, et al.
Journal of the National Cancer Institute|October 6, 2023
Trends in new and persistent opioid use in older adults with and without cancerLaura Van Metre Baum, Madhav Kc, Pamela R Soulos, et al.
JAMA Oncology|December 20, 2019
Idelalisib for Treatment of Relapsed Follicular Lymphoma and Chronic Lymphocytic Leukemia: A Comparison of Treatment Outcomes in Clinical Trial Participants vs Medicare BeneficiariesSteven T Bird, Fang Tian, Natasha Flowers, et al.
JAMA Internal Medicine|October 25, 2016
Association Between Changes in CMS Reimbursement Policy and Drug Labels for Erythrocyte-Stimulating Agents With Outcomes for Older Patients Undergoing Hemodialysis Covered by Fee-for-Service MedicareCunlin Wang, Robert Kane, Mark Levenson, et al.
Leukemia|June 11, 2020
Second cancers in adults with acute promyelocytic leukemia treated with or without arsenic trioxide: a SEER-medicare analysisKelly J Norsworthy, Armen Avagyan, Steven T Bird, et al.
Pharmacoepidemiology and Drug Safety|November 10, 2025
Validation of the US Food and Drug Administration's COVID-19 Disease Severity Categorization for Use in Real-World DataSilvia Perez-Vilar, Wei Hua, Andrew Kwist, et al.
Cancer|September 22, 2025
Opioid prescribing trends and pain scores among adult patients with cancer in a large health systemLaura Van Metre Baum, Pamela R Soulos, Madhav Kc, et al.
Pageof 17